We are live on ! Find out more
Frazier Life Sciences Management

Frazier Life Sciences Management Portfolio holdings

AUM $4.03B Turnover 19.15%
1-Year Est. Return 94.69%
 

Frazier Life Sciences is a biotech investment firm that backs companies developing new drugs, from their formation through to public markets. It started operations in 2022 and is owned mainly by Jamie Topper and Patrick Heron. Its Public Fund invests mainly in listed drug and biotech companies, with up to a fifth of its portfolio available for financings of private ones, while the firm's other funds mostly back private companies.

This Fund
S&P 500
This Quarter Est. Return
-4.89%
1 Year Est. Return
+94.69%
3 Year Est. Return
+692.48%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.06B
AUM Growth
-$114M
Cap. Flow
-$31M
Cap. Flow %
-2.92%
Top 10 Hldgs %
68.2%
Holding
44
New
2
Increased
8
Reduced
8
Closed
3
Avg Time Held
0.2 years
Top 10 Avg Time Held
0.2 years
Top 20 Avg Time Held
0.2 years

Sector Composition

Rank Sector Weight
1 Healthcare 98.6%
2 Miscellaneous 1.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
ARQT icon
1
Arcutis Biotherapeutics
ARQT
$3.57B
$180M 16.96%
8,434,232
– –
2022 Q1
1 quarter
HLVX icon
2
DELISTED
HilleVax
HLVX
$101M 9.58%
+9,285,682
New +$110M
2022 Q2
0 quarters
KRYS icon
3
Krystal Biotech
KRYS
$9.05B
$71.9M 6.79%
1,095,407
+229,157
+26% +$14.3M
2022 Q1
1 quarter
MIRM icon
4
Mirum Pharmaceuticals
MIRM
$6.14B
$69.4M 6.55%
3,566,912
– –
2022 Q1
1 quarter
KDNY
5
DELISTED
Chinook Therapeutics
KDNY
$62.9M 5.93%
3,595,026
+882,985
+33% +$13.9M
2022 Q1
1 quarter
SNDX icon
6
Syndax Pharmaceuticals
SNDX
$851M
$61.5M 5.8%
3,195,403
– –
2022 Q1
1 quarter
PHAT icon
7
Phathom Pharmaceuticals
PHAT
$493M
$49.2M 4.64%
5,827,415
– –
2022 Q1
1 quarter
SRRA
8
DELISTED
Sierra Oncology
SRRA
$47.9M 4.52%
870,636
-1,471,562
-63% -$77.2M
2022 Q1
1 quarter
IMGO
9
DELISTED
Imago BioSciences
IMGO
$39.8M 3.75%
2,971,274
– –
2022 Q1
1 quarter
PCVX icon
10
Vaxcyte
PCVX
$10B
$38.9M 3.67%
1,787,405
-522,149
-23% -$12.1M
2022 Q1
1 quarter
CRNX icon
11
DELISTED
Crinetics Pharmaceuticals
CRNX
$26.4M 2.49%
1,414,823
– –
2022 Q1
1 quarter
TARS icon
12
Tarsus Pharmaceuticals
TARS
$3.96B
$26.1M 2.46%
1,787,527
+370,370
+26% +$5.56M
2022 Q1
1 quarter
ALPN icon
13
DELISTED
Alpine Immune Sciences Inc
ALPN
$25.4M 2.4%
2,985,757
-1,200,000
-29% -$10.3M
2022 Q1
1 quarter
TCDA
14
DELISTED
Tricida
TCDA
$20.2M 1.9%
2,082,093
– –
2022 Q1
1 quarter
COGT icon
15
Cogent Biosciences
COGT
$4.97B
$18.9M 1.78%
2,094,154
-557,600
-21% -$3.81M
2022 Q1
1 quarter
ANAB icon
16
AnaptysBio
ANAB
$1.38B
$18.3M 1.72%
899,700
– –
2022 Q1
1 quarter
GRCL
17
DELISTED
Gracell Biotechnologies
GRCL
$17.1M 1.62%
3,111,551
-334,422
-10% -$1.04M
2022 Q1
1 quarter
KALV icon
18
DELISTED
KalVista Pharmaceuticals
KALV
$15.5M 1.46%
1,572,192
– –
2022 Q1
1 quarter
MRUS icon
19
DELISTED
Merus
MRUS
$15.3M 1.44%
673,979
+45,000
+7% +$939K
2022 Q1
1 quarter
FLACU
20
DELISTED
Frazier Lifesciences Acquisition Corp Unit
FLACU
$14.8M 1.4%
1,501,000
– –
2022 Q1
1 quarter
REPL icon
21
Replimune Group
REPL
$2.08B
$14.1M 1.33%
806,267
+89,505
+12% +$1.47M
2022 Q1
1 quarter
GRTS icon
22
DELISTED
Gritstone bio
GRTS
$12.7M 1.2%
5,237,348
– –
2022 Q1
1 quarter
ARVN icon
23
Arvinas
ARVN
$447M
$12M 1.13%
285,331
+15,000
+6% +$753K
2022 Q1
1 quarter
PASG icon
24
Passage Bio
PASG
$13.7M
$11.8M 1.12%
250,461
– –
2022 Q1
1 quarter
VRDN icon
25
Viridian Therapeutics
VRDN
$3.51B
$11.3M 1.07%
980,302
-759,228
-44% -$10.2M
2022 Q1
1 quarter

Similar funds

Frazier Life Sciences Management's Q2 2022 Portfolio in Review

As of Q2 2022, Frazier Life Sciences Management held 44 positions worth $1.06B, down 9.7% from $1.17B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Frazier Life Sciences Management's Q2 2022 filing shows 2 new, 8 increased, 8 reduced and 3 closed positions. Its largest new stake was HilleVax: 9,285,682 shares worth $101M. The largest sale was Sierra Oncology, an estimated $77.2M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous.

  • Frazier Life Sciences Management's largest Q2 2022 buy was HilleVax: 9,285,682 shares worth $101M.
  • Frazier Life Sciences Management added most to Krystal Biotech in Q2 2022, an estimated $14.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2022 reduction was Sierra Oncology, cutting an estimated $77.2M.
  • Frazier Life Sciences Management fully exited Bicycle Therapeutics in Q2 2022, selling an estimated $26.5M.
  • Frazier Life Sciences Management's ten largest holdings make up 68% of its $1.06B portfolio in Q2 2022.
  • Frazier Life Sciences Management opened 2 new positions and closed 3 in Q2 2022.
  • Frazier Life Sciences Management's portfolio value fell 9.7% quarter-over-quarter to $1.06B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2022, filed 10 Aug 2022.